A Phase II, Multicenter, Open-Label, Randomized Study Of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 17 Sep 2014
At a glance
- Drugs Sepantronium bromide (Primary) ; Docetaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 17 Sep 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Jul 2013 Planned end date changed from 1 Jun 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.
- 12 Apr 2013 Planned end date changed from 1 Dec 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History